Drugs moving into the clinic: 34

By Mike Nagle

- Last updated on GMT

Related tags: Heart, Metabolism

The latest in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
Sponsor Name Indication Mechanism
Palatin Technologies PL-3994 Cardiovascular - acute decompensated congestive heart failure (CHF)Long acting analog of atrial natriuretic peptide, which is involved in regulation of water and sodium levels in the circulation
Arete Therapeutics AR-9281 Cardiovascular - hypertension soluble epoxide hydrolase (s-EH) inhibitor - plays a key role in the cytochrome P450 pathway of arachidonic acid metabolism
Avigen AV411 (ibudilast) CNS - neuropathic painA glial attenuator that suppresses pro-inflammatory cytokines IL-1 beta, TNF alpha, and IL-6, and may upregulate the anti-inflammatory cytokine IL-10 - already approved in Japan
Avi Biopharma AVI-4658 Duchenne muscular dystrophy (DMD) Exon Skipping Pre-RNA Interference Technology
KeyNeurotek KN38-7271 CNS - stroke cannabinoid receptor agonist

Related topics: Preclinical Research

Related news

Show more

Follow us

Products

View more

Webinars